Zero krypton technology update prospectus: Alibaba health, Temasek, UBS and other star capital "scramble to raise" more than half

On July 1, Eastern time, zero krypton technology, a medical technology company, updated its prospectus (red herring version) to the SEC and planned to list on NASDAQ with "LDOC" as the securities code. The IPO was jointly underwritten by Morgan Stanley, Bank of America and CICC. According to the red herring version of the prospectus, zero krypton technology will issue 10.825 million ads shares, equivalent to four common shares each. The offering price ranges from US $17.5 to US $19.5 per ads, and the Underwriters enjoy a total of 1.624 million over allotment rights of ads. If the "green shoe mechanism" is implemented, the IPO will raise US $243 million. The IPO of zero krypton technology in the US stock market has received positive feedback from the market. According to its prospectus, there are six investors with clear investment intention (similar to the cornerstone investors listed in Hong Kong), including Alibaba health, Temasek and lake Bleu, as well as long-term fund UBS asset management, medical professional fund Hudson Bay and sage. The above-mentioned investment institutions and funds intend to subscribe for us $115 million. If the IPO is finally priced at US $18.5 per share, which is the middle end of the pricing range, the order amount of the six prospective investors will account for about 57.4% of the total financing amount, reflecting the confidence of old investors, long-term funds and medical professional funds in the future development of zero krypton.